Xenon Pharmaceuticals XENE Cash Flow Statement (2013-2026)

NASDAQ XENE
$36.27 +1.19 (+3.39%)
At close: Oct 20, 2026 · 4:00 PM EDT
Reported Financials

Xenon Pharmaceuticals Quarterly Cash Flow Statement

Periods 52 quarters
Latest Jun 2026

Xenon Pharmaceuticals reported cash from operations of -$95.39M and free cash flow of -$95.67M for the quarter ended Jun 2026, down 48.5% year over year. This cash flow statement covers 52 quarters of results from Sep 2013 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-15.45M-25.56M-19.67M-31.16M-37.15M-37.40M-41.73M-47.46M-48.46M-44.74M-47.93M-57.92M-62.79M-65.69M-65.05M-84.71M-90.90M-105.26M-102.30M-110.74M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
0.21M0.27M0.38M0.38M0.36M0.30M0.35M0.60M1.73M-0.63M0.59M0.64M0.67M0.67M0.66M0.63M0.64M0.61M0.59M0.56M
Share-based CompensationStock Comp.
2.64M2.71M3.61M5.21M5.74M5.81M5.99M8.45M8.74M9.18M9.40M14.72M13.00M13.60M12.17M13.71M13.71M14.12M16.89M16.73M
Deferred Taxes
-0.27M0.35M0.26M-0.10M-0.20M0.01M0.29M-0.22M-0.16M-0.20M0.40M-0.33M-0.32M-8.61M-1.21M-0.17M-0.70M-1.11M0.45M-1.94M
Gains from Investment SecuritiesGains Investment
0.02M-0.65M-3.36M-1.29M-0.29M2.01M1.88M1.04M0.49M0.15M-0.52M-0.09M-0.02M0.40M0.27M
Other non-cash itemsOther Non-Cash
0.44M-0.12M-0.14M0.63M2.96M0.09M-0.01M-0.45M-0.30M1.33M0.31M0.43M0.38M0.88M0.50M0.12M0.27M0.50M0.13M0.53M
Change in Working Capital
Change in ReceivablesChange Receivables
0.33M-0.48M0.16M-0.39M-0.01M-1.52M-0.23M-0.04M-0.16M0.29M-0.04M0.02M0.08M0.55M7.18M
Change in Accured ExpensesChange Accured Exp.
-1.27M3.76M-5.80M5.79M2.06M6.02M-0.59M5.58M-3.36M2.30M-5.02M9.15M-1.79M6.18M-3.78M0.87M5.23M3.19M-1.80M5.72M
Change in Other Operating AssetsOther Assets Change
0.14M1.03M0.27M-0.71M4.47M6.47M-2.93M-1.27M0.10M2.40M0.67M-0.97M-0.88M2.78M8.10M-2.07M3.09M-6.07M1.28M2.97M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.82M-2.20M-0.60M-0.30M-0.29M-0.31M-0.32M-0.31M-0.32M2.82M-0.29M-0.30M-0.32M
Other Working Capital ChangesOther WC Changes
-0.96M-3.23M-0.27M0.71M-4.47M-7.07M2.93M1.27M-0.10M-2.40M-0.97M0.68M0.56M-3.09M-8.41M1.75M-0.27M5.78M-1.58M-3.29M
Cash from OperationsCash from Ops.
-15.01M-20.71M-18.43M-16.87M-30.40M-35.33M-34.41M-33.22M-48.08M-35.40M-46.19M-31.15M-49.67M-54.39M-61.65M-64.23M-71.75M-81.48M-88.90M-95.39M
Investing Activities
Capital ExpendituresCapex
0.22M0.51M0.21M0.54M0.39M1.75M2.21M2.13M1.20M0.08M0.19M1.51M0.59M0.78M0.04M0.16M0.28M0.32M0.13M0.28M
Change in Property, Plant and EquipmentChange in PP&E
-0.22M-0.51M-0.21M-0.54M-0.39M-1.75M-2.21M-2.13M-1.20M-0.08M-0.19M-1.51M-0.59M-0.78M-0.04M-0.16M-0.28M-0.32M-0.13M-0.28M
Purchase of InvestmentsInvestments Purchased
10.00M257.19M68.96M72.68M294.76M114.74M108.28M162.27M146.77M376.59M176.85M124.98M164.09M66.35M131.24M88.82M74.70M60.90M505.65M490.38M
Sale and Maturity of InvestmentsInvestments Sold
25.80M42.28M20.28M74.54M61.04M104.76M157.11M192.31M201.85M136.88M133.84M235.68M165.18M165.64M165.79M171.23M113.51M123.92M98.50M159.42M
Cash from Investing ActivitiesCash from Investing
15.58M-215.43M-48.89M1.32M-234.10M-11.74M46.62M27.90M53.88M-239.79M-43.19M109.19M0.50M98.50M34.51M82.26M38.53M62.70M-407.28M-331.24M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Non-Current Debt
Net Debt Issuances and RepaymentsNet Debt Issuance
Change in Capital Stock
Common Stock IssuedStock Issued
0.03M0.02M7.88M277.77M-29.47M0.05M1.15M0.07M2.36M1.39M5.49M0.03M
Net Shares Issued and RepurchasedNet Shares Issued
0.03M0.02M7.88M277.77M-29.47M0.05M1.15M0.07M2.36M1.39M5.49M0.03M
Net Equity Issued and RepurchasedNet Equity Issued
0.03M0.02M7.88M277.77M-29.47M0.05M1.15M0.07M2.36M1.39M5.49M0.03M
Other financing activitiesOther financing
Cash from Financing ActivitiesCash from Financing
4.76M323.95M7.88M269.89M0.70M0.01M324.01M12.13M1.15M0.07M2.36M113.54M843.01M0.03M
Additional items
Exchange Rate EffectFX Effect
-0.45M0.07M0.29M-0.89M-2.70M0.81M0.06M0.36M-0.29M0.25M-0.37M-0.20M0.05M-1.16M-0.06M0.63M-0.01M-0.10M-0.13M0.26M
Change in Cash
4.88M87.88M-59.15M253.45M-266.50M-46.25M12.27M-4.96M35.02M49.07M-89.75M77.84M-49.11M55.09M-26.06M18.72M-30.87M94.65M346.70M-426.34M
Ending Cash Balance
87.81M175.69M116.54M369.99M103.49M57.24M69.51M64.55M99.57M148.64M58.90M136.73M87.62M142.71M116.66M135.38M104.51M199.16M545.87M119.53M
Free Cash FlowFCF
-15.23M-21.22M-18.64M-17.41M-30.79M-37.08M-36.62M-35.35M-49.28M-35.48M-46.38M-32.67M-50.26M-55.17M-61.70M-64.39M-72.03M-81.80M-89.03M-95.67M
Net Cash FlowNCF
5.33M87.81M-59.44M254.34M-263.80M-47.06M12.21M-5.32M5.80M48.82M-89.38M78.04M-49.17M56.25M-25.99M18.09M-30.86M94.75M346.83M-426.60M
Interest Paid
Income Taxes PaidTaxes Paid
1.65M

Xenon Pharmaceuticals Cash Flow Statement API

Pull Xenon Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=XENE&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY